The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

The Food and Drug Administration revised the existing approval of Keytruda, Herceptin and chemotherapy for patients with unresetable or metastatic HER2-positive gastric or gastroesophageal junction ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The combination of pembrolizumab and maintenance ...

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose. Patients with stage 4 non-small cell lung cancer (NSCLC) treated ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

DUBLIN--(BUSINESS WIRE)--The "KEYTRUDA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about ...

After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival. The approval in locally advanced ...